EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
BIO-Europe Spring EBD Group BIO BIO-Europe Spring
Share/Follow Us
Share this:
Follow this event:
Follow us on Twitter
Subscribe to our newsletters:

BIO-Europe Spring® 2016 Press Releases

July 30, 2014Spotlight on Stockholm/Uppsala Region Business Facts The Stockholm-Uppsala region, defined as the three counties of Uppsala, Stockholm and Sörmland, is one of the largest life science clusters in Europe. Stockholm-Uppsala region is Scandinavia's leading life science cluster and one of the world's most productive, and is one of the most competitive business environments in Europe. On average, an astounding 15–20 new...  more ►



partnering360:Insight Latest headlines from partnering360:Insight

August 29, 2015 HSCI fosters broad collaboration At the Harvard Stem Cell Institute (HSCI), "Partnering is important at all levels," emphasized Brock Reeve, executive director. That impetus is important not just in the sciences, but also among foundations, large and small companies and investors throughout the life sciences community. more ►

August 29, 2015 RA Capital: Flexibility builds innovation Flexibility is the watchword for investment at RA Capital Management. As Peter Kolchinsky, managing director, explained, "Investors should be as flexible as possible. Therefore, we're a crossover fund manager. We invest in biotechnology companies whether they are public or private companies and, increasingly, are putting our efforts into company formation." more ►

August 28, 2015 EBD partnering data dissected If you have attended any of our events, such as BIO-Europe┬«, then you know that they are a hive of partnering activity. Deals are plotted, shaped and consummated as thousands of executives shuttle between one-to-one meetings. If you are like us, then you are probably wondering which companies from what sector are getting the most attention.To get some answers, we asked IMS Health Capital (IMSHC), the investment banking arm of IMS Health, to analyze partnering data from our most recent conferences. more ►

August 8, 2015 Johnson & Johnson Innovation aims for disruption Johnson & Johnson Innovation, Boston, has high expectations for itself and its partners. "We're looking for ideas that will make a tremendous difference in patients' lives, not merely incremental progress," said Robert G. Urban, PhD, head of Johnson & Johnson Innovation, Boston. To do that, "we take advantage of the deep science emerging around us to develop bold platforms that make a big difference. more ►

July 21, 2015 Patient-centric Baxalta capitalizes on Cambridge When Baxalta Incorporated spun out of Baxter on July 1, it already qualified as "big pharma." With USD 6 billion in annual revenues, 16,000 employees, operations in 100 countries and USD 600 million invested in R&D, it focuses its assets tightly on the patient experience and expects its partners to do the same. more ►



Arrow Up


 
 

Follow this event: Follow us on Twitter
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2015 EBD GmbH
Privacy Policy and Cookies
Terms of Use